Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Generalized Pustular Psoriasis · Schizophrenia · VNDA

Vanda Pharmaceuticals Netherlands

Vanda Pharmaceuticals Netherlands B.V.

Vanda Pharmaceuticals Netherlands clinical programs — 60 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037, US HQ
2003 Founded
600 Employees
Public company Type
VNDA · NYSE Ticker
Company details
Status
Public
HQ
2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037, US
Founded
2003
Employees
600
Programs
60
Drugs
19
Patents
96
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Vanda Pharmaceuticals Netherlands projects

60 ClinicalTrials.gov programs sponsored by Vanda Pharmaceuticals Netherlands.

Vanda Pharmaceuticals Netherlands has 60 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

60 programs

Clinical programs

Page 1 of 2

  1. 20 mg VEC-162

    Vanda Pharmaceuticals Netherlands B.V.

    Insomnia

    phase 3 small molecule completed

    1 trial

  2. 750 mg Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Generalized Pustular Psoriasis

    phase 3 small molecule completed

    1 trial

  3. Double-blind 200 mg imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Generalized Pustular Psoriasis

    phase 3 small molecule terminated

    1 trial

  4. Iloperidone

    Vanda Pharmaceuticals Netherlands B.V.

    Bipolar I Disorder

    phase 3 small molecule completed

    2 trials

  5. Milsaperidone

    Vanda Pharmaceuticals Netherlands B.V.

    Major Depressive Disorder (MDD)

    phase 3 small molecule active

    1 trial

  6. Ponesimod

    Vanda Pharmaceuticals Netherlands B.V.

    Moderate-to-severe Chronic Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  7. Tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    Sleep Wake Disorders

    phase 3 small molecule active

    2 trials

  8. Tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    Jet Lag Type Insomnia

    phase 3 small molecule completed

    1 trial

  9. Tasimelteon Oral Suspension

    Vanda Pharmaceuticals Netherlands B.V.

    Insomnia Disorder

    phase 3 small molecule active

    1 trial

  10. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Nausea and Vomiting

    phase 3 small molecule active

    1 trial

  11. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Atopic Dermatitis

    phase 3 small molecule completed

    3 trials

  12. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Motion Sickness

    phase 3 small molecule active

    4 trials

  13. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Idiopathic Gastroparesis

    phase 3 small molecule active

    2 trials

  14. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Coronavirus Infection

    phase 3 small molecule active

    1 trial

  15. VEC-162 20 mg

    Vanda Pharmaceuticals Netherlands B.V.

    Primary Insomnia

    phase 3 small molecule completed

    1 trial

  16. VP-VEC-162-3601

    Vanda Pharmaceuticals Netherlands B.V.

    Autism Spectrum Disorder

    phase 3 small molecule active

    1 trial

  17. VP-VHX-896-3201

    Vanda Pharmaceuticals Netherlands B.V.

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  18. VQW-765

    Vanda Pharmaceuticals Netherlands B.V.

    Social Anxiety Disorder (SAD)

    phase 3 small molecule active

    1 trial

  19. tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  20. tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    Non 24 Hour Sleep Wake Disorder

    phase 3 small molecule active

    4 trials

  21. tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    Smith-Magenis Syndrome

    phase 3 small molecule completed

    1 trial

  22. Iloperidone

    Vanda Pharmaceuticals Netherlands B.V.

    Parkinson Disease Psychosis

    phase 2 small molecule terminated

    1 trial

  23. Iloperidone crystalline formulation

    Vanda Pharmaceuticals Netherlands B.V.

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  24. Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Generalized Pustular Psoriasis

    phase 2 mab completed

    1 trial

  25. Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Palmoplantar Pustulosis

    phase 2 mab completed

    1 trial

  26. Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Ichthyosis

    phase 2 small molecule terminated

    1 trial

  27. Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Hidradenitis Suppurativa

    phase 2 mab completed

    1 trial

  28. Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Acneiform Eruptions

    phase 2 mab terminated

    1 trial

  29. Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Acne Vulgaris

    phase 2 small molecule completed

    1 trial

  30. Tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    Jet Lag Disorder

    phase 2 small molecule completed

    1 trial

  31. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Obesity

    phase 2 small molecule completed

    1 trial

  32. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Healthy Volunteer

    phase 2 small molecule completed

    1 trial

  33. Trichostatin A

    Vanda Pharmaceuticals Netherlands B.V.

    Onychomycosis of Toenail

    phase 2 small molecule active

    1 trial

  34. VCA-894A

    Vanda Pharmaceuticals Netherlands B.V.

    Charcot Marie Tooth Disease (CMT)

    phase 2 small molecule active

    1 trial

  35. VEC-162

    Vanda Pharmaceuticals Netherlands B.V.

    Circadian Rhythm Sleep Disorders

    phase 2 small molecule completed

    1 trial

  36. VLY-686

    Vanda Pharmaceuticals Netherlands B.V.

    Treatment-resistant Pruritus Associated With Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  37. VLY-686 (Tradipitant)

    Vanda Pharmaceuticals Netherlands B.V.

    Gastroparesis

    phase 2 small molecule completed

    1 trial

  38. VQW-765

    Vanda Pharmaceuticals Netherlands B.V.

    Performance Anxiety

    phase 2 small molecule completed

    1 trial

  39. VSF-173

    Vanda Pharmaceuticals Netherlands B.V.

    Excessive Somnolence

    phase 2 small molecule completed

    1 trial

  40. VSJ-110

    Vanda Pharmaceuticals Netherlands B.V.

    Dry Eye

    phase 2 small molecule active

    2 trials

  41. VSJ-110

    Vanda Pharmaceuticals Netherlands B.V.

    Allergic Conjunctivitis

    phase 2 small molecule completed

    1 trial

  42. iloperidone

    Vanda Pharmaceuticals Netherlands B.V.

    Hypertension

    phase 2 small molecule active

    1 trial

  43. Tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    REM Behavior Disorder

    phase 1 small molecule terminated

    1 trial

  44. Tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  45. Tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    4 trials

  46. Tasimelteon Oral Capsule

    Vanda Pharmaceuticals Netherlands B.V.

    Healthy

    phase 1 small molecule completed

    1 trial

  47. Trichostatin A

    Vanda Pharmaceuticals Netherlands B.V.

    Relapsed or Refractory Hematologic Malignancies

    phase 1 small molecule active

    1 trial

  48. VHX-896

    Vanda Pharmaceuticals Netherlands B.V.

    Healthy

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Vanda Pharmaceuticals Netherlands have?

60 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.